Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced Non-Small Cell Lung Cancer(NSCLC).

NCT05068427 is registered in ClinicalTrials.gov with Chipscreen Biosciences, Ltd. as lead sponsor.

NCT NCT05068427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05068427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced Non-Small Cell Lung Cancer(NSCLC).
Lead sponsor
Chipscreen Biosciences, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 23, 2021
Completion date
May 16, 2024
Enrollment
34 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer